media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Hisun Pharmaceutical’s prostate cancer treatment drug has been approved for market launch

Recently, Hisun Pharmaceutical announced that it has received a Drug Registration Certificate for apalutamide tablets (60mg) issued by the National Medical Products Administration (NMPA) for the treatment of adult patients with metastatic endocrine therapy-sensitive prostate cancer (mHSPC) and adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) with a high risk of metastasis. According to the “Analysis of the Epidemiological Situation of Malignant Tumors in China in 2022” released by the National Cancer Center in 2024, the number of newly diagnosed prostate cancer cases reached 134,000, and the number of deaths reached 48,000, ranking sixth among male malignant tumors. As one of the most common malignant tumors in men, there is a strong market demand for apalutamide. According to IQVIA database statistics, global sales of apalutamide tablets are estimated at approximately US$5.202 billion in 2025, with domestic sales in China accounting for approximately US$85.7771 million. https://mp.weixin.qq.com/s/m2Q8h0C5A-yyIwBwEyudCw
- Source: drugdu
- 68
- May 26, 2026
Huadong Medicine’s first precision-targeting EGFR exon 21 (L858R) innovative drug, mefanilinib maleate (Mindray®), was prescribed for the first time nationwide

Recently, the first prescription of Mindray®, Huadong Medicine’s first precision-targeted EGFR exon 21 (L858R) innovative drug, was successfully issued at Shantou Central Hospital. This marks the official commercialization of Mindray® in China, propelling the treatment of non-small cell lung cancer (NSCLC) in my country into a new era of precision-targeted therapy and bringing new hope for survival to patients with locally advanced or metastatic NSCLC suffering from EGFR exon 21 (L858R) substitution mutations! Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80%-85% of primary lung cancers. In my country, about 70% of NSCLC patients are diagnosed at an advanced stage, resulting in a low five-year survival rate. EGFR exon 21 (L858R) mutation is the major subtype of EGFR mutations, accounting for 35%-41%. Patients with exon 21 (L858R) mutations exhibit more specific clinical characteristics: older age, a higher proportion ...
- Source: drugdu
- 62
- May 26, 2026
Progen Pharmaceuticals’ metoprolol succinate extended-release tablets have received FDA approval in the United States for a new 25mg specification.

Recently, Zhejiang Jutai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Progen Pharmaceuticals, received approval from the U.S. Food and Drug Administration (FDA) for a new 25mg PAS (Metoprolol Succinate Extended-Release Tablet) specification. This is another significant development following the FDA approval of the 50mg, 100mg, and 200mg specifications of the product in 2024, marking Progen Pharmaceuticals’ comprehensive multi-specification coverage of this core formulation in the U.S. market. Metoprolol succinate extended-release tablets are the world’s first selective β1 receptor blocker, which can reduce the risk of bronchoconstriction. It is widely used in the treatment of hypertension, angina pectoris, and symptomatic stable chronic heart failure with left ventricular systolic dysfunction, and is a commonly used drug in the field of chronic heart failure. Data shows that in 2025, the sales of this drug in the US market were approximately $233 million. The successful approval of the 25mg specification further improves the product ...
- Source: drugdu
- 53
- May 26, 2026
Japanese pharmaceutical giant ordered to pay 17 billion yen in damages.

A major ruling recently came from the U.S. District Court in Boston: Japanese pharmaceutical giant Takeda Pharmaceutical lost its first-instance case in a “pay-for-delay” antitrust lawsuit, with a federal jury ordering it to pay initial damages of $885 million . Under the triple damages clause of U.S. antitrust law, this fine could ultimately soar to approximately $2.5 billion (about 17 billion yuan) . ” Payment Delay ” agreements are a controversial business arrangement that has long existed in the pharmaceutical industry. The core logic is that when original drug manufacturers face patent challenges from generic drug manufacturers, they pay substantial compensation or share market profits in exchange for the generic drug manufacturers voluntarily abandoning their patent challenges and delaying the launch of their products. This case revolves around Takeda’s constipation treatment drug Amitiza (rubiprostone) . Developed by Sucampo and co-marketed by Takeda, the drug quickly became a blockbuster product after ...
- Source: drugdu
- 72
- May 26, 2026
Big news! Johnson & Johnson’s new autoimmune drug nicalimab approved in China

Recently, the NMPA (National Medical Products Administration) announced the launch of Johnson & Johnson’s nicarlimumab injection (trade name: Anliwei® ), for use in combination with conventional therapies to treat adult patients and adolescents older than 12 years with autoantibodies-positive generalized myasthenia gravis (gMG). This marks another significant milestone for nicarlimumab globally, following its FDA approval last April and subsequent approval by the European Commission, and also signifies the arrival of a strong new competitor in the field of precision treatment for gMG in China. In August 2020, Johnson & Johnson announced its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion, with its core objective being this investigational FcRn antibody. On April 30, 2025, nicarlimumab received initial FDA approval in the United States (trade name IMAAVY®) for the treatment of patients aged 12 years and older with positive anti-AChR or anti-MuSK antibodies in generalized myasthenia gravis. Subsequently, the European Commission also ...
- Source: drugdu
- 65
- May 26, 2026
Health & Hygiene Expo

Organiser：Bangladesh Exhibitions Pvt. Ltd. Time：November 5–7, 2026 Address：Plot# 66, Block#C, Umme kulsum Road, Bashundhara R/ A, Dhaka-1229, Dhaka Exhibition hall：International Convention City, Bashundhara Dhaka Product range: Sanitation & Hygiene Solutions | Personal & Household Hygiene | Air & Water Purification Systems | Waste Management & Recycling | Workplace & Industrial Hygiene | Public Health & Safety Equipment | Protective & Safety Gear (PPE) | Healthcare & Health Solutions | Sanitation & Disinfection Equipment | Community Health Solutions About Health & Hygiene Expo： Health & Hygiene Expo Dhaka is the most authoritative health and hygiene exhibition in Bangladesh. Dedicated to showcasing the latest advancements and innovations in the health industry, it is an unmissable event for professionals, experts, and enthusiasts from across the country and around the globe. With over 285 exhibitors currently on board, the expo will deliver a comprehensive and diverse display of the latest products in ...
- Source: drugdu
- 53
- May 26, 2026
Qilu Pharmaceutical’s generic version of “Sinimod tablets” has been approved for marketing, aiming to rival Novartis

Multiple sclerosis (MS) is a severe, lifelong, progressive, and highly disabling autoimmune chronic disease of the central nervous system (CNS). It commonly affects the periventricular region, juxtacortex, optic nerve, spinal cord, brainstem, and cerebellum, exhibiting spatial and temporal dissemination. Incidence and prevalence are correlated with geographic distribution and ethnicity. On May 21, 2026, according to the latest information on the official website of the National Medical Products Administration (NMPA) of China, Qilu Pharmaceutical Co., Ltd. ‘s application for sinimod tablets was approved for marketing. Public information shows that sinimod tablets are a sphingosine-1-phosphate (S1P) receptor modulator used to treat relapsing-remitting multiple sclerosis in adults , including active secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and clinically isolated syndrome. It is worth mentioning that on the same day, Kelun Pharmaceutical’s application for sinimod tablets was also approved for marketing , making both pharmaceutical companies the first generic versions of this drug ...
- Source: drugdu
- 72
- May 25, 2026
Unprecedented! Three domestically produced ustekinumab drugs received approval within two days, completely ending the era of original drug monopoly

From May 21st to 22nd, 2026, the National Medical Products Administration (NMPA) issued a series of major drug approvals, with biosimilars of ustekinumab from three major domestic pharmaceutical companies—Huadong Medicine, Bio-Thera Solutions, and CSPC Pharmaceutical Group—receiving approval for marketing in quick succession , creating an unprecedented surge in approvals in the domestic autoimmune biologics field. Specifically, Huadong Medicine and Bio-Thera Solutions simultaneously obtained approval for Crohn’s disease indications on May 21st, both for intravenous infusion and subcutaneous injection formulations; while CSPC Pharmaceutical Group’s Enyike® officially received approval for plaque psoriasis indications on May 22nd. This round of approvals completely ends the six-year monopoly of the original Johnson & Johnson Stardenafil®, significantly expands the range of autoimmune disease treatment options in China, and brings more affordable and higher-quality domestic treatment options to millions of patients with psoriasis and inflammatory bowel disease in China. The urgent need of millions of patients: a ...
- Source: drugdu
- 82
- May 25, 2026
First! FDA approves Gilead’s liver therapy

On May 22, 2026, the FDA announced accelerated approval for Gilead ‘s Hepcludex (bulevirtide) injection for the treatment of chronic hepatitis D virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Screenshot source: FDAThis approval not only marks the official birth of the first treatment for chronic HDV infection in the United States, but also fills a long-standing clinical gap in the field.HDV infection occurs only in individuals infected with hepatitis B virus (HBV), and can take the form of co-infection or superinfection. Compared to HBV infection alone, co-infection with HDV accelerates the progression of liver fibrosis and significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver disease-related death .Hepcludex was approved based on data from a Phase III clinical trial called MYR301. Results showed that at week 48, patients treated with Hepcludex 8.5 mg once daily had a comprehensive response rate (significantly reduced viral load and ...
- Source: drugdu
- 62
- May 25, 2026
Lunan Pharmaceutical’s Lilin® Bortezomib for Injection has been approved for marketing and is considered to have passed the evaluation

Recently, Lilin® Bortezomib for Injection (specifications: 1.0mg, 3.5mg) produced by Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group , was approved for marketing by the National Medical Products Administration and is considered to have passed the consistency evaluation of generic drug quality and efficacy. The approval numbers are: National Drug Approval Number H20264387 and National Drug Approval Number H20264388. The active ingredient in this product is bortezomib, a reversible inhibitor of chymotrypsin-like activity of the 26S proteasome in mammalian cells. It induces tumor cell apoptosis by inhibiting proteasome function, interfering with the ubiquitin-proteasome pathway, and blocking the degradation of key signaling proteins within tumor cells. Preclinical studies have shown its significant inhibitory effect on tumors such as multiple myeloma. When used for multiple myeloma, this product can be combined with melphalan and prednisone (MP regimen) for previously untreated patients who are not suitable for high-dose chemotherapy ...
- Source: drugdu
- 58
- May 25, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.